title: Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
abstract: Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In univariable analysis, female gender, greater number of prior therapies, Rai stages III-IV, adenopathy ≥ 10 cm, splenomegaly, del(11q), decreased albumin and increased absolute lymphocyte count, white blood cell count (WBC), β2-microglobulin, and lactate dehydrogenase were associated (P < 0.05) with TLS. In multivariable analysis, female gender, adenopathy ≥ 10 cm, elevated WBC, increased β2-microglobulin, and decreased albumin were associated with TLS (P < 0.05). With respect to patient outcomes, 49 and 44% of patients with and without TLS, respectively, responded to flavopiridol (P = 0.71). In a multivariable analysis, controlling for number of prior therapies, cytogenetics, Rai stage, age and gender, progression-free survival (PFS) was inferior in patients with TLS (P = 0.01). Female patients and patients with elevated β2-microglobulin, increased WBC, adenopathy ≥ 10 cm and decreased albumin were at highest risk and should be monitored for TLS with flavopiridol. TLS does not appear to be predictive of response or improved PFS in patients receiving flavopiridol.
authors: Division of Hematology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, OH 43210, USA. kristie.blum@osumc.edu
authors: K A
authors: KA
authors: Blum
authors: A S
authors: AS
authors: Ruppert
authors: J A
authors: JA
authors: Woyach
authors: J A
authors: JA
authors: Jones
authors: L
authors: L
authors: Andritsos
authors: J M
authors: JM
authors: Flynn
authors: B
authors: B
authors: Rovin
authors: M
authors: M
authors: Villalona-Calero
authors: J
authors: J
authors: Ji
authors: M
authors: M
authors: Phelps
authors: A J
authors: AJ
authors: Johnson
authors: M R
authors: MR
authors: Grever
authors: J C
authors: JC
authors: Byrd
references: J Clin Oncol. 2008 Jun 1;26(16):2767-78
references: 18509186
references: N Engl J Med. 2000 Dec 28;343(26):1910-6
references: 11136261
references: Blood. 2000 Jul 15;96(2):393-7
references: 10887097
references: Blood. 1998 Nov 15;92(10):3804-16
references: 9808574
references: Blood. 2007 Jan 15;109(2):399-404
references: 17003373
references: Haematologica. 2000 Dec;85(12):1268-70
references: 11114133
references: Clin Cancer Res. 2005 Jun 1;11(11):4176-81
references: 15930354
references: N Engl J Med. 1993 Nov 18;329(21):1547-8
references: 8105383
references: J Clin Oncol. 2009 Dec 10;27(35):6012-8
references: 19826119
references: J Clin Oncol. 1998 Jul;16(7):2313-20
references: 9667245
references: Blood. 1996 Jun 15;87(12):4990-7
references: 8652811
references: Leuk Res. 2005 Nov;29(11):1253-7
references: 15916806
references: J Clin Oncol. 2010 Jun 20;28(18):3015-22
references: 20479412
references: Br J Haematol. 2010 May;149(4):578-86
references: 20331465
references: J Clin Oncol. 1999 Mar;17(3):791-5
references: 10071268
references: J Clin Oncol. 2007 Mar 20;25(9):1114-20
references: 17296974
references: Blood. 2009 Mar 19;113(12):2637-45
references: 18981292
references: Haematologica. 2008 Dec;93(12):1877-85
references: 18838473